591 related articles for article (PubMed ID: 18202967)
1. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.
Dupuy AM; Carrière I; Scali J; Cristol JP; Ritchie K; Dartigues JF; Gambert P; Ancelin ML
Climacteric; 2008 Feb; 11(1):74-83. PubMed ID: 18202967
[TBL] [Abstract][Full Text] [Related]
2. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study.
Dufouil C; Richard F; Fiévet N; Dartigues JF; Ritchie K; Tzourio C; Amouyel P; Alpérovitch A
Neurology; 2005 May; 64(9):1531-8. PubMed ID: 15883313
[TBL] [Abstract][Full Text] [Related]
3. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
4. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
5. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
6. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group.
Connelly PW; Stachenko S; MacLean DR; Petrasovits A; Little JA
Can J Cardiol; 1999 Apr; 15(4):419-27. PubMed ID: 10322251
[TBL] [Abstract][Full Text] [Related]
8. Relationship between plasma lipids and all-cause mortality in nondemented elderly.
Schupf N; Costa R; Luchsinger J; Tang MX; Lee JH; Mayeux R
J Am Geriatr Soc; 2005 Feb; 53(2):219-26. PubMed ID: 15673344
[TBL] [Abstract][Full Text] [Related]
9. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
Gouni-Berthold I; Krone W
Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581
[TBL] [Abstract][Full Text] [Related]
10. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
Dobiásová M; Frohlich J
Vnitr Lek; 2000 Mar; 46(3):152-6. PubMed ID: 11048517
[TBL] [Abstract][Full Text] [Related]
11. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
12. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
Imperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
Minerva Ginecol; 2003 Feb; 55(1):87-93. PubMed ID: 12598849
[TBL] [Abstract][Full Text] [Related]
13. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
14. Lipids in type 2 diabetes.
Laakso M
Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596
[TBL] [Abstract][Full Text] [Related]
15. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
[TBL] [Abstract][Full Text] [Related]
16. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
Devroey D; Velkeniers B; Duquet W; Betz W
Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
[TBL] [Abstract][Full Text] [Related]
17. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of dyslipidemia in clinical practice].
Paragh G; Harangi M
Orv Hetil; 2006 Mar; 147(9):389-94. PubMed ID: 16619956
[TBL] [Abstract][Full Text] [Related]
19. Achieving vascular risk factor targets: a survey of a London general practice.
Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
[TBL] [Abstract][Full Text] [Related]
20. Optimal management of cholesterol levels and the prevention of coronary heart disease in women.
Mosca LJ
Am Fam Physician; 2002 Jan; 65(2):217-26. PubMed ID: 11820486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
